Gast ::
| Hauptseite > Publikationsdatenbank > Imaging of adenosine receptors > print |
| 001 | 201924 | ||
| 005 | 20210129215945.0 | ||
| 024 | 7 | _ | |a WOS:000348578700228 |2 WOS |
| 024 | 7 | _ | |a 1573-9538 |2 ISSN |
| 024 | 7 | _ | |a 1573-9546 |2 ISSN |
| 037 | _ | _ | |a FZJ-2015-04214 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Elmenhorst, David. |0 P:(DE-Juel1)131679 |b 0 |e Corresponding Author |u fzj |
| 111 | 2 | _ | |a Purines 2014 |c Bonn |d 2014-07-23 - 2014-07-27 |w Germany |
| 245 | _ | _ | |a Imaging of adenosine receptors |
| 260 | _ | _ | |a Dordrecht |c 2014 |b Springer Science + Business Media B.V. |
| 300 | _ | _ | |a 744-744 |
| 336 | 7 | _ | |a Contribution to a conference proceedings |b contrib |m contrib |0 PUB:(DE-HGF)8 |s 1435298094_21794 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |m journal |
| 336 | 7 | _ | |a Conference Paper |0 33 |2 EndNote |
| 336 | 7 | _ | |a CONFERENCE_PAPER |2 ORCID |
| 336 | 7 | _ | |a Output Types/Conference Paper |2 DataCite |
| 336 | 7 | _ | |a conferenceObject |2 DRIVER |
| 336 | 7 | _ | |a INPROCEEDINGS |2 BibTeX |
| 520 | _ | _ | |a Over the last decades adenosine receptor ligands, agonists as well as antagonists, have been developed. The requirements for compounds suitable for non-invasivein vivo imaging of adenosine receptors (radiopharmaceuticals, radiotracers) with positron emission tomography (PET) are in several aspects different from thosefor therapeutic drugs. This difference will be elucidated for radiotracers involved in human neurotransmission research.In humans theA1 adenosine receptor (A1AR) shows themost abundant distribution and highest concentrations in brain cortical and subcortical areas, whereas theA2Aadenosine receptor (A2AAR) can be found in selected regions like striatum, nucleus accumbens, olfactory tubercle. A2B adenosine receptors (A2BAR) and A3 adenosinereceptors (A3ARs) are expressed in low levels in the brain.Most of the imaging probes therefore target the A1AR and A2AAR. The talk will give an overview of currentlyused imaging probes and applications. The neuroreceptor imaging technique has been used for example to investigate physiological mechanisms of the sleep wakeregulation or pathophysiological conditions like cerebral ischemia, ethanol intoxication, epilepsy or Alzheimer’s disease in humans and animal models. Pharmacokineticanalysis of PET experiments allow additionally to investigate drug action in the human brain, like for example the impact of caffeine on A1AR availability. |
| 536 | _ | _ | |a 333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333) |0 G:(DE-HGF)POF2-333 |c POF2-333 |f POF II |x 0 |
| 588 | _ | _ | |a Dataset connected to Web of Science, Web of Science, , juser.fz-juelich.de |
| 700 | 1 | _ | |a Kroll, Tina. |0 P:(DE-Juel1)131691 |b 1 |u fzj |
| 700 | 1 | _ | |a Matusch, Andreas. |0 P:(DE-Juel1)138474 |b 2 |u fzj |
| 700 | 1 | _ | |a Bauer, Andreas |0 P:(DE-Juel1)131672 |b 3 |u fzj |
| 773 | _ | _ | |n 4 |0 PERI:(DE-600)2172143-9 |t Purinergic signalling |v 10 |y 2014 |x 1573-9538 |
| 909 | C | O | |o oai:juser.fz-juelich.de:201924 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)131679 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)131691 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)138474 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)131672 |
| 913 | 2 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-571 |2 G:(DE-HGF)POF3-500 |v Connectivity and Activity |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Funktion und Dysfunktion des Nervensystems |1 G:(DE-HGF)POF2-330 |0 G:(DE-HGF)POF2-333 |2 G:(DE-HGF)POF2-300 |v Pathophysiological Mechanisms of Neurological and Psychiatric Diseases |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF2 |
| 914 | 1 | _ | |y 2015 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 0 |
| 980 | _ | _ | |a contrib |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|